» Articles » PMID: 35008317

The Intricate Interplay Between Cell Cycle Regulators and Autophagy in Cancer

Overview
Journal Cancers (Basel)
Publisher MDPI
Specialty Oncology
Date 2022 Jan 11
PMID 35008317
Authors
Affiliations
Soon will be listed here.
Abstract

In the past decade, cell cycle regulators have extended their canonical role in cell cycle progression to the regulation of various cellular processes, including cellular metabolism. The regulation of metabolism is intimately connected with the function of autophagy, a catabolic process that promotes the efficient recycling of endogenous components from both extrinsic stress, e.g., nutrient deprivation, and intrinsic sub-lethal damage. Mediating cellular homeostasis and cytoprotection, autophagy is found to be dysregulated in numerous pathophysiological contexts, such as cancer. As an adaptative advantage, the upregulation of autophagy allows tumor cells to integrate stress signals, escaping multiple cell death mechanisms. Nevertheless, the precise role of autophagy during tumor development and progression remains highly context-dependent. Recently, multiple articles has suggested the importance of various cell cycle regulators in the modulation of autophagic processes. Here, we review the current clues indicating that cell-cycle regulators, including cyclin-dependent kinase inhibitors (CKIs), cyclin-dependent kinases (CDKs), and E2F transcription factors, are intrinsically linked to the regulation of autophagy. As an increasing number of studies highlight the importance of autophagy in cancer progression, we finally evoke new perspectives in therapeutic avenues that may include both cell cycle inhibitors and autophagy modulators to synergize antitumor efficacy.

Citing Articles

TQFL19, a Novel Derivative of Thymoquinone (TQ), Plays an Essential Role by Inhibiting Cell Growth, Metastasis, and Invasion in Triple-Negative Breast Cancer.

El-Far A, Liu X, Xiao T, Du J, Du X, Wei C Molecules. 2025; 30(4).

PMID: 40005083 PMC: 11858164. DOI: 10.3390/molecules30040773.


Autophagy in Tissue Repair and Regeneration.

Moreno-Blas D, Adell T, Gonzalez-Estevez C Cells. 2025; 14(4).

PMID: 39996754 PMC: 11853389. DOI: 10.3390/cells14040282.


CDK4 inactivation inhibits apoptosis via mitochondria-ER contact remodeling in triple-negative breast cancer.

Ziegler D, Parashar K, Leal-Esteban L, Lopez-Alcala J, Castro W, Zanou N Nat Commun. 2025; 16(1):541.

PMID: 39788939 PMC: 11718081. DOI: 10.1038/s41467-024-55605-z.


HBx promotes tumorigenicity through RRM2-mediated autophagy in hepatocellular carcinoma.

Li Y, Wang F, Geng Z, He T, Song Y, Wu J Cell Biosci. 2024; 14(1):116.

PMID: 39256879 PMC: 11389268. DOI: 10.1186/s13578-024-01298-2.


A comprehensive review of computational cell cycle models in guiding cancer treatment strategies.

Ma C, Gurkan-Cavusoglu E NPJ Syst Biol Appl. 2024; 10(1):71.

PMID: 38969664 PMC: 11226463. DOI: 10.1038/s41540-024-00397-7.


References
1.
Taguchi N, Ishihara N, Jofuku A, Oka T, Mihara K . Mitotic phosphorylation of dynamin-related GTPase Drp1 participates in mitochondrial fission. J Biol Chem. 2007; 282(15):11521-9. DOI: 10.1074/jbc.M607279200. View

2.
Weinmann A, Bartley S, Zhang T, Zhang M, Farnham P . Use of chromatin immunoprecipitation to clone novel E2F target promoters. Mol Cell Biol. 2001; 21(20):6820-32. PMC: 99859. DOI: 10.1128/MCB.21.20.6820-6832.2001. View

3.
Klein M, Kovatcheva M, Davis L, Tap W, Koff A . CDK4/6 Inhibitors: The Mechanism of Action May Not Be as Simple as Once Thought. Cancer Cell. 2018; 34(1):9-20. PMC: 6039233. DOI: 10.1016/j.ccell.2018.03.023. View

4.
Fingar D, Richardson C, Tee A, Cheatham L, Tsou C, Blenis J . mTOR controls cell cycle progression through its cell growth effectors S6K1 and 4E-BP1/eukaryotic translation initiation factor 4E. Mol Cell Biol. 2003; 24(1):200-16. PMC: 303352. DOI: 10.1128/MCB.24.1.200-216.2004. View

5.
Shamloo B, Usluer S . p21 in Cancer Research. Cancers (Basel). 2019; 11(8). PMC: 6721478. DOI: 10.3390/cancers11081178. View